JDJonathan Diep

Jonathan Diep

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jonathan Diep has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Carolyn R. Bertozzi

    Department of Chemistry, Stanford University, Stanford, CA 94305, USA

    1 shared publication
  • Christine E. Peters

    Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, USA

    1 shared publication
  • Christopher M. Richards

    Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, USA

    1 shared publication
  • Claude M. Nagamine

    Department of Comparative Medicine, Stanford University School of Medicine, Stanford, USA

    1 shared publication
  • David S. Roberts

    Department of Chemistry, Stanford University, Stanford, USA

    1 shared publication
  • Erik de Vries

    Virology group, Division of Infectious Diseases and Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands

    1 shared publication

Latest Publications

  • Top Cited Papers

    MFSD6 is an entry receptor for enterovirus D68

    by Lauren Varanese, Lily Xu, Christine E. Peters, Grigore Pintilie, David S. Roberts, Suyash Raj, Mengying Liu, Yaw Shin Ooi, Jonathan Diep, Wenjie Qiao, et al.

    With the near eradication of poliovirus due to global vaccination campaigns, attention has shifted to other enteroviruses that can cause polio-like paralysis syndrome (now termed acute flaccid myelitis (AFM))1–3. In particular, enterovirus D68 (EV-D68) is believed to be the main driver of epidemic outbreaks of AFM in recent years4, yet not much is known about EV-D68 host interactions. EV-D68 is a respiratory virus5 but, in rare cases, can spread to the central nervous system to cause severe neuropathogenesis. Here, we used genome-scale CRISPR screens to identify the poorly characterized multipass membrane transporter MFSD6 as a host entry factor for EV-D68. Knockout of MFSD6 expression abrogated EV-D68 infection in cell lines and primary cells corresponding to respiratory and neural cells. MFSD6 localized to the plasma membrane and was required for viral entry into host cells. MFSD6 bound directly to EV-D68 particles via its third extracellular loop (L3). We determined the cryo-EM structure of EV-D68 in complex with L3 at 2.1 Å resolution, revealing the interaction interface. A decoy receptor, engineered by fusing MFSD6(L3) to Fc, blocked EV-D68 infection of human primary lung epithelial cells, and provided near complete protection in a lethal mouse model of EV-D68 infection. Collectively, our results reveal MFSD6 as an entry receptor for EV-D68, and support targeting MFSD6 as a potential mechanism to combat infections by this emerging pathogen with pandemic potential.


  • Open Access

    Microfluidic chip‐based single‐cell cloning to accelerate biologic production timelines

    by Jonathan Diep, Huong Le, Kim Le, Ewelina Zasadzinska, Jasmine Tat, Pheng Yam, Ryan Zastrow, Natalia Gomez, Jennitte Stevens

    Cell line development (CLD) represents a critical, yet time‐consuming, step in the biomanufacturing process as significant resources are devoted to the scale‐up and screening of several hundreds to thousands of single‐cell clones. Typically, transfected pools are fully recovered from selection and characterized for growth, productivity, and product quality to identify the best pools suitable for single‐cell cloning (SCC) using limiting dilution or fluorescence‐activated cell sorting (FACS). Here we report the application of the Berkeley Lights Beacon Instrument (BLI) in an early SCC process to accelerate the CLD timeline. Transfected pools were single‐cell cloned when viabilities reached greater than 85% or during selection when viabilities were less than 30%. Clones isolated from these accelerated processes exhibited comparable growth, productivity, and product quality to those derived from a standard CLD process and fit into an existing manufacturing platform. With these approaches, up to a 30% reduction in the overall CLD timeline was achieved. Furthermore, early process‐derived clones demonstrated equivalent long‐term stability compared with standard process‐derived clones over 50 population doubling levels (PDLs). Taken together, the data supported early SCC on the BLI as an attractive approach to reducing the standard CLD timeline while still identifying clones with acceptable manufacturability.